StockNews.com downgraded shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Thursday morning. Other research analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their price objective on Invitae from $1.50 to $1.00 and set a […]
Invitae Co. (NYSE:NVTA – Free Report) – Equities researchers at William Blair raised their Q3 2023 earnings per share (EPS) estimates for Invitae in a report issued on Wednesday, August 16th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of ($0.31) per share for the quarter, up from […]
/PRNewswire/ BACKGROUND: According to the American Cancer Society (ACS), as of January 2022, it is estimated that there are 18.1 million cancer survivors in.
Nikko Asset Management Americas Inc. lessened its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 0.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 17,256,161 shares of the medical research company’s stock after selling 19,190 shares during the period. Nikko Asset Management Americas Inc. owned approximately 0.07% of Invitae worth $32,096,000 as […]
Swiss National Bank increased its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 4.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 539,600 shares of the medical research company’s stock after buying an additional 23,100 shares during […]